Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Int J Biol Markers. 2011 Sep 21;26(3):141–152. doi: 10.5301/JBM.2011.8613

Fig. 1.

Fig. 1

Comparative performance of urine and serum biomarkers in ovarian cancer. Urines obtained from 118 patients diagnosed with ovarian cancer, 118 women with benign pelvic conditions, and 72 healthy controls were evaluated using Luminex multiplexed immunoassays for 15 biomarkers found to be informative in 2 previous analyses in serum. Biomarker level distributions in urine and serum are presented along with ROC curves and AUC values (solid line: urine; dashed line: serum). A. Urine biomarker levels from ovarian cancer patients and healthy controls are compared with serum biomarker levels from a previous report (22). B. Urine biomarker levels from ovarian cancer patients and benign controls are compared with serum biomarker levels from a previous report (21). Biomarkers demonstrating significantly elevated AUC levels, based on 95% confidence intervals, in urine versus serum are shown.